메뉴 건너뛰기




Volumn 23, Issue 3, 2010, Pages 210-214

Long-acting depot formulations of naltrexone for heroin dependence: A review

Author keywords

Heroin dependence; Long acting sustained release formulations; Naltrexone

Indexed keywords

BUPRENORPHINE; DEPOTREX; METHADONE; NALTREXONE; PLACEBO; UNCLASSIFIED DRUG;

EID: 77952239984     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3283386578     Document Type: Review
Times cited : (57)

References (21)
  • 1
    • 38549099015 scopus 로고    scopus 로고
    • Pharmacologic treatments for opioid dependence: Detoxification and maintenance options
    • Kleber H. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci 2007;9:455-470.
    • (2007) Dialogues Clin. Neurosci. , vol.9 , pp. 455-470
    • Kleber, H.1
  • 2
    • 33750464502 scopus 로고    scopus 로고
    • Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in st. Petersburg, russia
    • Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006;31:319-328.
    • (2006) J. Subst Abuse Treat , vol.31 , pp. 319-328
    • Krupitsky, E.M.1    Zvartau, E.E.2    Masalov, D.V.3
  • 3
    • 33846096441 scopus 로고    scopus 로고
    • Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence
    • Volpicelli RG, Fenton M. Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurol 2006;1:389-398.
    • (2006) Future Neurol. , vol.1 , pp. 389-398
    • Volpicelli, R.G.1    Fenton, M.2
  • 4
    • 36348931537 scopus 로고    scopus 로고
    • Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence
    • Dunbar JL, Turncliff RZ, Hayes SC, et al. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs 2007;68:862-870.
    • (2007) J. Stud Alcohol Drugs , vol.68 , pp. 862-870
    • Dunbar, J.L.1    Turncliff, R.Z.2    Hayes, S.C.3
  • 5
    • 32244444572 scopus 로고    scopus 로고
    • Injectable, sustained-release naltrexone for the treatment of opioid dependence
    • Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence. Arch Gen Psychiatry 2006;63:210-218.
    • (2006) Arch. Gen. Psychiatry , vol.63 , pp. 210-218
    • Comer, S.D.1    Sullivan, M.A.2    Yu, E.3
  • 6
    • 33644771227 scopus 로고    scopus 로고
    • Single-and multiple-dose pharmacokinetics of Long-acting injectable naltrexone
    • Dunbar JL, Turncliff RZ, Dong Q, et al. Single-and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 2006;30: 480-490.
    • (2006) Alcohol Clin. Exp. Res. , vol.30 , pp. 480-490
    • Dunbar, J.L.1    Turncliff, R.Z.2    Dong, Q.3
  • 7
    • 47549113312 scopus 로고    scopus 로고
    • Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone
    • This clinical case demonstrates that it is possible to overcome opioid blockade with Vivitrol and precipitate withdrawal in some circumstances
    • Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction 2008;103:1399-1401. This clinical case demonstrates that it is possible to overcome opioid blockade with Vivitrol and precipitate withdrawal in some circumstances.
    • (2008) Addiction , vol.103 , pp. 1399-1401
    • Fishman, M.1
  • 8
    • 34250353080 scopus 로고    scopus 로고
    • Overcoming opioid blockade from depot naltrexone (prodetoxon®)
    • Kruptisky EM, Burakov AM, Tsoy MV, et al. Overcoming opioid blockade from depot naltrexone (Prodetoxon®). Addiction 2007;102:1164-1165.
    • (2007) Addiction , vol.102 , pp. 1164-1165
    • Kruptisky, E.M.1    Burakov, A.M.2    Tsoy, M.V.3
  • 9
    • 34447282259 scopus 로고    scopus 로고
    • A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant
    • Iyer SS, Barr WH, Karnes HT. A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant. Int J Pharm 2007;340 (1-2) :119-125.
    • (2007) Int. J. Pharm. , vol.340 , Issue.1-2 , pp. 119-125
    • Iyer, S.S.1    Barr, W.H.2    Karnes, H.T.3
  • 10
    • 34447251651 scopus 로고    scopus 로고
    • A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant
    • IyerSS, Barr WH, Dance ME, et al. A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant. Int J Pharm 2007;340 (1-2) :104-118.
    • (2007) Int. J. Pharm. , vol.340 , Issue.1-2 , pp. 104-118
    • Iyer, S.S.1    Barr, W.H.2    Dance, M.E.3
  • 13
    • 77952243821 scopus 로고    scopus 로고
    • The Long term use of prodetoxone in the treatment of opiate dependence
    • Russian
    • Boiko EO. The long term use of Prodetoxone in the treatment of opiate dependence. Narcologiya (Addict Med) 2007;3:21-24. (in Russian).
    • (2007) Narcologiya (Addict Med) , vol.3 , pp. 21-24
    • Boiko, E.O.1
  • 14
    • 38549097156 scopus 로고    scopus 로고
    • Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program
    • Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007;2:35.
    • (2007) Subst Abuse Treat Prev Policy , vol.2 , pp. 35
    • Reece, A.S.1
  • 15
    • 70349667302 scopus 로고    scopus 로고
    • Improving clinical outcomes in treating heroin dependence
    • This first double-blind, placebo-controlled, randomized clinical trial showed the effectiveness of a single dose of the Australian naltrexone implant in comparison with oral naltrexone
    • Hulse GK, Morris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence. Arch Gen Psychiatry 2009;66:1108-1115. This first double-blind, placebo-controlled, randomized clinical trial showed the effectiveness of a single dose of the Australian naltrexone implant in comparison with oral naltrexone.
    • (2009) Arch. Gen. Psychiatry , vol.66 , pp. 1108-1115
    • Hulse, G.K.1    Morris, N.2    Arnold-Reed, D.3
  • 16
    • 67649207399 scopus 로고    scopus 로고
    • Naltrexone implants after in-patient treatment for opioid dependence: Randomized controlled trial
    • This study done in Norway compares oral naltrexone and Australian implantable naltrexone
    • Kunoe N, Lobmaier P, Vederhus JK, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomized controlled trial. Br J Psychiatry 2009;194:541-546. This study done in Norway compares oral naltrexone and Australian implantable naltrexone.
    • (2009) Br. J. Psychiatry , vol.194 , pp. 541-546
    • Kunoe, N.1    Lobmaier, P.2    Vederhus, J.K.3
  • 18
    • 69349084677 scopus 로고    scopus 로고
    • Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine
    • Reece AS. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine. J Subst Abuse Treat 2009;37:256-265.
    • (2009) J. Subst Abuse Treat , vol.37 , pp. 256-265
    • Reece, A.S.1
  • 19
    • 42049087623 scopus 로고    scopus 로고
    • Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance therapy or naltrexone implantation
    • Ngo HTT, Tait RJ, Hulse GK. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance therapy or naltrexone implantation. Arch Gen Psychiatry 2008;65:457-465.
    • (2008) Arch. Gen. Psychiatry , vol.65 , pp. 457-465
    • Ngo, H.T.T.1    Tait, R.J.2    Hulse, G.K.3
  • 20
    • 47349122953 scopus 로고    scopus 로고
    • Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment
    • Tait RG, Ngo HTT, Hulse GH. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 2008;35: 116-124.
    • (2008) J. Subst Abuse Treat , vol.35 , pp. 116-124
    • Tait, R.G.1    Ngo, H.T.T.2    Hulse, G.H.3
  • 21
    • 36549041776 scopus 로고    scopus 로고
    • Depot naltrexone use for opioid dependence in Australia: Large-scale use of an unregistered medication in the absence of data on safety and efficacy
    • Degenhardt L, Gibson A, Mattick RP, et al. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy. Drug Alcohol Rev 2008;27:1-3.
    • (2008) Drug Alcohol Rev. , vol.27 , pp. 1-3
    • Degenhardt, L.1    Gibson, A.2    Mattick, R.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.